Open AccessAlzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?
Author(s) -
Allison B. Reiss,
Amy D. Glass,
Thomas Wısnıewskı,
Benjamin Wolozin,
Irving H. Gomolin,
Aaron Pinkhasov,
Joshua De Leon,
Mark M. Stecker
Publication year - 2020
Publication title -
journal of investigative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.879
H-Index - 66
eISSN - 1708-8267
pISSN - 1081-5589
DOI - 10.1136/jim-2020-001297
Subject(s) - disease , medicine , clinical trial , neuroscience , cognition , alzheimer's disease , pathogenesis , cognitive decline , amyloid β , cognitive impairment , intervention (counseling) , central nervous system , bioinformatics , psychology , pathology , dementia , psychiatry , biology
Alzheimer's disease (AD) is a neurodegenerative brain disorder associated with relentlessly progressive cognitive impairment and memory loss. AD pathology proceeds for decades before cognitive deficits become clinically apparent, opening a window for preventative therapy. Imbalance of clearance and buildup of amyloid β and phosphorylated tau proteins in the central nervous system is believed to contribute to AD pathogenesis. However, multiple clinical trials of treatments aimed at averting accumulation of these proteins have yielded little success, and there is still no disease-modifying intervention. Here, we discuss current knowledge of AD pathology and treatment with an emphasis on emerging biomarkers and treatment strategies.